All Stories

  1. WFSBP guidelines on how to grade treatment evidence for clinical guideline development

    Article • The World Journal of Biological Psychiatry, December 2018, Taylor & Francis

    Hans-Juergen Moeller, Kamyar Keramatian

  2. Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety

    Article • The World Journal of Biological Psychiatry, September 2018, Taylor & Francis

    Hans-Juergen Moeller

  3. Silexan in anxiety disorders: Clinical data and pharmacological background

    Article • The World Journal of Biological Psychiatry, June 2017, Taylor & Francis

    Hans-Juergen Moeller

  4. Why are new antidepressants failing to make the grade for approval?

    Article • Expert Opinion on Pharmacotherapy, April 2017, Taylor & Francis

    Hans-Juergen Moeller

  5. Psychiatrie, Psychosomatik, Psychotherapie

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  6. Psychiatrie, Psychosomatik, Psychotherapie

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  7. Psychopharmakotherapie – klinisch-empirische Grundlagen

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  8. Standardisierte Befunddiagnostik in der Psychiatrie

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  9. Prinzipien der Methodik empirischer Forschung in der Psychiatrie

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  10. Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  11. Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes

    Article • January 2017, Springer Science + Business Media

    Hans-Juergen Moeller

  12. Speaker 1: Hans Jürgen Möller, Germany

    Article • The International Journal of Neuropsychopharmacology, May 2016, Oxford University Press (OUP)

    Hans-Juergen Moeller

  13. Speaker 4: Hans-Jürgen Möller, Germany

    Article • The International Journal of Neuropsychopharmacology, May 2016, Oxford University Press (OUP)

    Hans-Juergen Moeller

  14. Pharmacological treatment of underlying psychiatric disorders in suicidal patients

    Article • January 2016, Oxford University Press (OUP)

    Hans-Juergen Moeller

  15. Evidenzbasierung und leitliniengeschützte Therapie in der Psychiatrie

    Article • January 2016, Springer Science + Business Media

    Hans-Juergen Moeller

  16. Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes

    Article • January 2016, Springer Science + Business Media

    Hans-Juergen Moeller

  17. Pharmacological treatment of negative symptoms in schizophrenia

    Article • European Archives of Psychiatry and Clinical Neuroscience, April 2015, Springer Science + Business Media

    Hans-Juergen Moeller

  18. Standardisierte Befunddiagnostik in der Psychiatrie

    Article • January 2015, Springer Science + Business Media

    Hans-Juergen Moeller

  19. Psychiatrie, Psychosomatik und Psychotherapie

    Article • January 2015, Thieme Publishing Group

    Hans-Juergen Moeller

  20. Psychiatric Assessment: Negative Symptoms

    Article • January 2015, Elsevier

    Hans-Juergen Moeller

  21. Prinzipien der Methodik empirischer Forschung in der Psychiatrie

    Article • January 2015, Springer Science + Business Media

    Hans-Juergen Moeller

  22. A proposal for an updated neuropsychopharmacological nomenclature

    Article • European Neuropsychopharmacology, July 2014, Elsevier

    Hans-Juergen Moeller

  23. Are antidepressants clinically useful? Conclusion of a decade of debate

    Article • World Psychiatry, June 2014, Wiley

    Hans-Juergen Moeller

  24. The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy

    Article • International Journal of Psychiatry in Clinical Practice, February 2014, Taylor & Francis

    Hans-Juergen Moeller

  25. Guide to Assessment Scales in Major Depressive Disorder

    Article • January 2014, Springer Science + Business Media

    Hans-Juergen Moeller

  26. History, background, concepts and current use of comedication and polypharmacy in psychiatry

    Article • The International Journal of Neuropsychopharmacology, September 2013, Oxford University Press (OUP)

    Hans-Juergen Moeller

  27. Neuropsychological functioning in inpatients with major depression or schizophrenia

    Article • BMC Psychiatry, August 2013, Springer Science + Business Media

    Hans-Juergen Moeller

  28. Risikofaktoren für Suizide und Suizidversuche an einem Universitätsklinikum

    Article • Psychiatrische Praxis, July 2013, Thieme Publishing Group

    Hans-Juergen Moeller

  29. The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm”

    Article • International Journal of Psychiatry in Clinical Practice, April 2013, Taylor & Francis

    Hans-Juergen Moeller

  30. Impulsivity is related to striatal dopamine transporter availability in healthy males

    Article • Psychiatry Research Neuroimaging, March 2013, Elsevier

    Hans-Juergen Moeller

  31. Treatment-resistant Depression

    Article • February 2013, Wiley

    Hans-Juergen Moeller

  32. Reliability and plasticity of response inhibition and interference control

    Article • Brain and Cognition, February 2013, Elsevier

    Hans-Juergen Moeller

  33. Psychiatrie, Psychosomatik und Psychotherapie

    Article • January 2013, Thieme Publishing Group

    Hans-Juergen Moeller

  34. Psychosis during treatment with isotretinoin

    Article • Therapeutic Advances in Psychopharmacology, December 2012, SAGE Publications

    Hans-Juergen Moeller

  35. Treatment Response in First-episode Schizophrenia

    Article • Clinical Psychopharmacology and Neuroscience, August 2012, Korean College of Neuropsychopharmacology (KAMJE)

    Hans-Juergen Moeller

  36. The new impact factor in 2011 of EAPCN

    Article • European Archives of Psychiatry and Clinical Neuroscience, August 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  37. Infectious agents are associated with psychiatric diseases

    Article • Mental Illness, July 2012, PAGEPress Publications

    Hans-Juergen Moeller

  38. Biomarkers and neurobiology of schizophrenia

    Article • European Archives of Psychiatry and Clinical Neuroscience, June 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  39. Was Psychiatriepatienten den Schlaf raubt

    Article • MMW - Fortschritte der Medizin, June 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  40. From pathophysiological aspects towards unravelling the neurobiological background of cognitive deficits

    Article • European Archives of Psychiatry and Clinical Neuroscience, May 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  41. Pharmacotherapy of Schizophrenic Patients: Achievements, Unsolved Needs, Future Research Necessities

    Article • Current Pharmaceutical Biotechnology, May 2012, Bentham Science Publishers

    Hans-Juergen Moeller

  42. Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome

    Article • Current Psychiatry Reports, April 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  43. Psychopathology: genetics and the stress-vulnerability hypothesis

    Article • European Archives of Psychiatry and Clinical Neuroscience, March 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  44. Schizotypy and Behavioural Adjustment and the Role of Neuroticism

    Article • PLoS ONE, February 2012, PLOS

    Hans-Juergen Moeller

  45. Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?

    Article • BMC Medicine, February 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  46. Creatine Protects against Excitoxicity in an In Vitro Model of Neurodegeneration

    Article • PLoS ONE, February 2012, PLOS

    Hans-Juergen Moeller

  47. Psychiatrie in Europa: Stand der Dinge, Chancen und Herausforderungen

    Article • January 2012, Springer Science + Business Media

    Hans-Juergen Moeller

  48. Antipsychotic Response in the First Week Predicts Later Efficacy

    Article • Neuropsychobiology, January 2012, Karger Publishers

    Hans-Juergen Moeller

  49. How close is evidence to truth in evidence-based treatment of mental disorders?

    Article • European Archives of Psychiatry and Clinical Neuroscience, November 2011, Springer Science + Business Media

    Hans-Juergen Moeller

  50. Functional neural correlates of psychometric schizotypy: An fMRI study of antisaccades

    Article • Psychophysiology, November 2011, Wiley

    Hans-Juergen Moeller, Veena Kumari

  51. Methylphenidate effects on neural activity during response inhibition in healthy humans

    Article • Pharmacopsychiatry, September 2011, Thieme Publishing Group

    Hans-Juergen Moeller

  52. Antidepressiva bei leichten depressiven Störungen

    Article • Psychiatrische Praxis, August 2011, Thieme Publishing Group

    Hans-Juergen Moeller

  53. State of the Art: Treatment of Bipolar Disorders

    Article • CNS Neuroscience & Therapeutics, July 2011, Wiley

    Hans-Juergen Moeller

  54. Is the PANSS used correctly? a systematic review

    Article • BMC Psychiatry, July 2011, Springer Science + Business Media

    Hans-Juergen Moeller

  55. Antidepressants vs. placebo: not merely a quantitative difference in response

    Article • The International Journal of Neuropsychopharmacology, June 2011, Oxford University Press (OUP)

    Hans-Juergen Moeller

  56. Reception of Kraepelin's ideas 1900-1960

    Article • Psychiatry and Clinical Neurosciences, June 2011, Wiley

    Hans-Juergen Moeller

  57. Is evaluation of humorous stimuli associated with frontal cortex morphology? A pilot study using facial micro-movement analysis and MRI

    Article • Cortex, May 2011, Elsevier

    Hans-Juergen Moeller

  58. Biological Perspectives on Psychiatry for the Person

    Article • The International Journal of Person Centered Medicine, April 2011, University of Buckingham Press

    Hans-Juergen Moeller

  59. Bücher

    Article • Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie, March 2011, Springer Science + Business Media

    Hans-Juergen Moeller

  60. Effectiveness of Quetiapine in Outpatients With Schizophrenia Assessed Under "Real-Life" Conditions

    Article • Journal of Clinical Psychopharmacology, February 2011, Wolters Kluwer Health

    Hans-Juergen Moeller

  61. Memorix Psychiatrie und Psychotherapie

    Article • January 2011, Thieme Publishing Group

    Hans-Juergen Moeller

  62. Konsiliarpsychiatrie und -psychotherapie

    Article • January 2011, Thieme Publishing Group

    Hans-Juergen Moeller

  63. Gruss- und Nachworte (Epilogues)

    Article • January 2011, Elsevier

    Hans-Juergen Moeller

  64. Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients

    Article • January 2011, Springer Science + Business Media

    Hans-Juergen Moeller

  65. Suicidality and Outcome in Schizophrenia Patients

    Article • January 2011, Springer Science + Business Media

    Hans-Juergen Moeller

  66. Sleep, hypothalamus, and stigma

    Article • European Archives of Psychiatry and Clinical Neuroscience, November 2010, Springer Science + Business Media

    Hans-Juergen Moeller

  67. Understanding mental disorders from neuronal networks to glial cells and proteomics

    Article • European Archives of Psychiatry and Clinical Neuroscience, September 2010, Springer Science + Business Media

    Hans-Juergen Moeller

  68. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data

    Article • The International Journal of Neuropsychopharmacology, August 2010, Oxford University Press (OUP)

    Hans-Juergen Moeller

  69. Is the Overlap of Neurobiological and Psychopathological Parameters Large Enough to Give up the Dichotomic Classification?

    Article • Psychiatric Annals, March 2010, SLACK, Inc.

    Hans-Juergen Moeller

  70. Methodik

    Article • January 2010, Springer Science + Business Media

    Hans-Juergen Moeller

  71. Der besondere Stellenwert von Antipsychotika der zweiten Generation in der Therapie schizophrener und affektiver Psychosen

    Article • January 2010, Springer Science + Business Media

    Hans-Juergen Moeller

  72. Agomelatine: relief ensured at each and every stage of depression

    Article • Annals of General Psychiatry, January 2010, Springer Science + Business Media

    Hans-Juergen Moeller

  73. Social disability in schizophrenic, schizoaffective and affective disorders 15years after first admission

    Article • Schizophrenia Research, January 2010, Elsevier

    Hans-Juergen Moeller

  74. Meta-analyses: a method to maximise the evidence from clinical studies?

    Article • European Archives of Psychiatry and Clinical Neuroscience, November 2009, Springer Science + Business Media

    Hans-Juergen Moeller

  75. Principle standards and problems regarding proof of efficacy in clinical psychopharmacology

    Article • European Archives of Psychiatry and Clinical Neuroscience, November 2009, Springer Science + Business Media

    Hans-Juergen Moeller

  76. Is evidence sufficient for evidence-based medicine?

    Article • European Archives of Psychiatry and Clinical Neuroscience, October 2009, Springer Science + Business Media

    Hans-Juergen Moeller

  77. Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations

    Article • European Archives of Psychiatry and Clinical Neuroscience, October 2009, Springer Science + Business Media

    Hans-Juergen Moeller

  78. The free choice whether or not to respond after stimulus presentation

    Article • Human Brain Mapping, September 2009, Wiley

    Hans-Juergen Moeller

  79. Side effect burden of antipsychotic medication

    Article • September 2009, Taylor & Francis

    Hans-Juergen Moeller

  80. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

    Article • International Clinical Psychopharmacology, May 2009, Wolters Kluwer Health

    Hans-Juergen Moeller

  81. Do “real world” studies on antipsychotics tell us the real truth?

    Article • World Psychiatry, February 2009, Wiley

    Hans-Juergen Moeller

  82. Antidepressants and suicidality in younger adults - is bipolar illness the missing link?

    Article • Acta Psychiatrica Scandinavica, February 2009, Wiley

    Hans-Juergen Moeller

  83. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression

    Article • European Archives of Psychiatry and Clinical Neuroscience, January 2009, Springer Science + Business Media

    Hans-Juergen Moeller

  84. Psychiatrie und Psychotherapie

    Article • January 2009, Thieme Publishing Group

    Hans-Juergen Moeller

  85. Pharmacological and other biological treatments of suicidal individuals

    Article • January 2009, Oxford University Press (OUP)

    Hans-Juergen Moeller

  86. Therapieentscheidung aufgrund von Metaanalysen

    Article • Psychiatrische Praxis, November 2008, Thieme Publishing Group

    Hans-Juergen Moeller

  87. Neuropsychological impairments predict the clinical course in schizophrenia

    Article • European Archives of Psychiatry and Clinical Neuroscience, November 2008, Springer Science + Business Media

    Hans-Juergen Moeller

  88. „Wir sind auf einem guten Weg“

    Article • MMW - Fortschritte der Medizin, October 2008, Springer Science + Business Media

    Hans-Juergen Moeller

  89. Temperament and character of suicide attempters

    Article • Journal of Psychiatric Research, September 2008, Elsevier

    Hans-Juergen Moeller, Raffaella Calati

  90. Single-trial coupling of EEG and fMRI reveals the involvement of early anterior cingulate cortex activation in effortful decision making

    Article • NeuroImage, August 2008, Elsevier

    Hans-Juergen Moeller

  91. Do SSRIs or antidepressants in general increase suicidality?

    Article • European Archives of Psychiatry and Clinical Neuroscience, July 2008, Springer Science + Business Media

    Hans-Juergen Moeller

  92. Do effectiveness (“real world”) studies on antipsychotics tell us the real truth?

    Article • European Archives of Psychiatry and Clinical Neuroscience, July 2008, Springer Science + Business Media

    Hans-Juergen Moeller

  93. P4-342: Only mild cognitive impairment/Alzheimer's disease shows a significant cognitive improvement receiving combined antidementive treatment

    Article • Alzheimer s & Dementia, July 2008, Elsevier

    Hans-Juergen Moeller

  94. COURSE OF SCHIZOPHRENIA: A CRITERION FOR CLASSIFICATION?

    Article • Schizophrenia Research, June 2008, Elsevier

    Hans-Juergen Moeller

  95. Systematic of psychiatric disorders between categorical and dimensional approaches

    Article • European Archives of Psychiatry and Clinical Neuroscience, May 2008, Springer Science + Business Media

    Hans-Juergen Moeller

  96. Duloxetine in the treatment of major psychiatric and neuropathic disorders

    Article • Expert Review of Neurotherapeutics, April 2008, Taylor & Francis

    Hans-Juergen Moeller

  97. The assessment of cognitive impairment would be a relevant addition to the criteria for diagnosing schizophrenia

    Article • World Psychiatry, February 2008, Wiley

    Hans-Juergen Moeller

  98. Memorix Psychiatrie und Psychotherapie

    Article • January 2008, Thieme Publishing Group

    Hans-Juergen Moeller

  99. Psychiatrie und Psychotherapie

    Article • January 2008, Springer Science + Business Media

    Hans-Juergen Moeller

  100. EDITORIAL

    Article • The World Journal of Biological Psychiatry, January 2008, Taylor & Francis

    Hans-Juergen Moeller

  101. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

    Article • The World Journal of Biological Psychiatry, January 2008, Taylor & Francis

    Hans-Juergen Moeller

  102. Drug Treatment of Depressive Symptoms in Schizophrenia

    Article • Clinical Schizophrenia & Related Psychoses, January 2008, Walsh Medical Media, LLC

    Hans-Juergen Moeller

  103. How to grade categories of evidence

    Article • The World Journal of Biological Psychiatry, January 2008, Taylor & Francis

    Hans-Juergen Moeller

  104. Hans-Jürgen Möller, Herausgeber: Therapie psychischer Erkrankungen

    Article • Schweizer Archiv für Neurologie und Psychiatrie, December 2007, EMH Swiss Medical Publishers, Ltd.

    Hans-Juergen Moeller

  105. Priorität für atypische Neuroleptika

    Article • Psychiatrische Praxis, November 2007, Thieme Publishing Group

    Hans-Juergen Moeller

  106. Editorial: Paving the way to remission: the melatonergic approach in depression

    Article • International Clinical Psychopharmacology, October 2007, Wolters Kluwer Health

    Hans-Juergen Moeller

  107. Evidence of agomelatineʼs antidepressant efficacy: the key points

    Article • International Clinical Psychopharmacology, October 2007, Wolters Kluwer Health

    Hans-Juergen Moeller

  108. Clinical evaluation of negative symptoms in schizophrenia

    Article • European Psychiatry, September 2007, Elsevier

    Hans-Juergen Moeller

  109. Influence of Anxiety on Electrophysiological Correlates of Response Inhibition Capacities in Alcoholism

    Article • Clinical EEG and Neuroscience, April 2007, SAGE Publications

    Hans-Juergen Moeller

  110. Hinweise der AkdÄ und KBV zu Quetiapin und anderen modernen Antipsychotika - Richtigstellung der DGPPN

    Article • psychoneuro, February 2007, Thieme Publishing Group

    Hans-Juergen Moeller

  111. Depression

    Article • January 2007, Thieme Publishing Group

    Hans-Juergen Moeller

  112. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders

    Article • The World Journal of Biological Psychiatry, January 2007, Taylor & Francis

    Hans-Juergen Moeller

  113. Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition

    Article • Depression and Anxiety, January 2007, Wiley

    Hans-Juergen Moeller

  114. Do effectiveness studies tell us the real truth?

    Article • The World Journal of Biological Psychiatry, January 2007, Taylor & Francis

    Hans-Juergen Moeller

  115. Hans-Jürgen Möller, Norbert Müller, Herausgeber: Aktuelle Aspekte der Pathogenese und Therapie der Schizophrenie

    Article • Schweizer Archiv für Neurologie und Psychiatrie, December 2006, EMH Swiss Medical Publishers, Ltd.

    Hans-Juergen Moeller

  116. Antidepressants and Driving Ability

    Article • The Journal of Clinical Psychiatry, November 2006, Physicians Postgraduate Press, Inc

    Hans-Juergen Moeller

  117. IC–P–041: Multivariate network analysis of fiber tract integrity in Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2006, Wiley

    Olaf Dietrich, Hans-Juergen Moeller

  118. IC-P-065

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Hans-Juergen Moeller

  119. P2-323

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Hans-Juergen Moeller

  120. IC-P-060

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Hans-Juergen Moeller

  121. P3-425

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Hans-Juergen Moeller

  122. S4-02-03

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Hans-Juergen Moeller

  123. Evidence for beneficial effects of antidepressants on suicidality in depressive patients

    Article • European Archives of Psychiatry and Clinical Neuroscience, June 2006, Springer Science + Business Media

    Hans-Juergen Moeller

  124. Long-acting risperidone: Focus on safety

    Article • Clinical Therapeutics, May 2006, Elsevier

    Hans-Juergen Moeller

  125. Duloxetine: a new selective and dual-acting antidepressant

    Article • Expert Opinion on Pharmacotherapy, February 2006, Informa Healthcare

    Hans-Juergen Moeller

  126. Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression

    Article • Current Pharmaceutical Design, February 2006, Bentham Science Publishers

    Hans-Juergen Moeller

  127. Hans-Jürgen Möller, Norbert Müller, Herausgeber: Schizophrenie: Langzeitverlauf und Langzeittherapie

    Article • Schweizer Archiv für Neurologie und Psychiatrie, January 2006, EMH Swiss Medical Publishers, Ltd.

    Hans-Juergen Moeller

  128. Therapie psychischer Erkrankungen

    Article • January 2006, Thieme Publishing Group

    Hans-Juergen Moeller

  129. Aktuelle Aspekte der Pathogenese und Therapie der Schizophrenie

    Article • January 2006, Springer Science + Business Media

    Hans-Juergen Moeller

  130. Das Publizieren in der Psychiatrie

    Article • January 2006, Springer Science + Business Media

    Hans-Juergen Moeller

  131. Akut- und Langzeittherapie der Depression (ICD-10 F3)

    Article • January 2006, Elsevier

    Hans-Juergen Moeller

  132. Innovation und Wandel der antidepressiven Therapie in Deutschland

    Article • January 2006, Thieme Publishing Group

    Hans-Juergen Moeller

  133. Progress in Pharmacopsychiatry

    Article • European Neurological Review, January 2006, Touch Digital Media, Ltd.

    Hans-Juergen Moeller

  134. GABAAreceptors as targets for novel anxiolytic drugs

    Article • The World Journal of Biological Psychiatry, January 2006, Taylor & Francis

    Hans-Juergen Moeller

  135. Ethical aspects of publishing

    Article • The World Journal of Biological Psychiatry, January 2006, Taylor & Francis

    Hans-Juergen Moeller

  136. Treatment of depression with atypical features: A meta-analytic approach

    Article • Psychiatry Research, January 2006, Elsevier

    Hans-Juergen Moeller

  137. Metaanalyses—highest level of empirical evidence?

    Article • European Archives of Psychiatry and Clinical Neuroscience, December 2005, Springer Science + Business Media

    Hans-Juergen Moeller

  138. Antipsychotika bei Demenz

    Article • psychoneuro, November 2005, Thieme Publishing Group

    Hans-Juergen Moeller

  139. CATIE: Die Auswahl von Antipsychotika bei Schizophrenie

    Article • psychoneuro, October 2005, Thieme Publishing Group

    Hans-Juergen Moeller

  140. Antidepressiva: Lebensgefährliche Plazebos? - Arznei-Telegramm: fahrlässiges Journal

    Article • psychoneuro, October 2005, Thieme Publishing Group

    Hans-Juergen Moeller

  141. Zielvereinbarung 2005 zwischen GKV und KV-Hamburg - Ausgabensenkung um 1 % u.a. bei Antidepressiva blockiert Teilhabe der Kranken am Fortschritt

    Article • psychoneuro, September 2005, Thieme Publishing Group

    Hans-Juergen Moeller

  142. Antipsychotic and antidepressive effects of second generation antipsychotics

    Article • European Archives of Psychiatry and Clinical Neuroscience, June 2005, Springer Science + Business Media

    Hans-Juergen Moeller

  143. Risperidone: a review

    Article • Expert Opinion on Pharmacotherapy, May 2005, Informa Healthcare

    Hans-Juergen Moeller

  144. Stigma - Diskriminierung - Bewältigung

    Article • psychoneuro, March 2005, Thieme Publishing Group

    Hans-Juergen Moeller

  145. Problems associated with the classification and diagnosis of psychiatric disorders

    Article • The World Journal of Biological Psychiatry, March 2005, Taylor & Francis

    Hans-Juergen Moeller

  146. Psychiatrie und Psychotherapie

    Article • January 2005, Thieme Publishing Group

    Hans-Juergen Moeller

  147. Are placebo-controlled studies required in order to prove efficacy of antidepressants?

    Article • The World Journal of Biological Psychiatry, January 2005, Taylor & Francis

    Hans-Juergen Moeller

  148. Evidence of Depressive Mixed States

    Article • American Journal of Psychiatry, January 2005, American Psychiatric Association

    Hans-Juergen Moeller

  149. Öffentlichkeitsaufklärung - Entstigmatisierung schizophrener Erkrankungen

    Article • psychoneuro, November 2004, Thieme Publishing Group

    Hans-Juergen Moeller

  150. Optimierung der pharmakologischen Langzeitbehandlung ersterkrankter schizophrener Patienten

    Article • psychoneuro, November 2004, Thieme Publishing Group

    Hans-Juergen Moeller

  151. The bipolar spectrum: diagnostic and pharmacologic considerations

    Article • Expert Review of Neurotherapeutics, November 2004, Taylor & Francis

    Hans-Juergen Moeller

  152. Targets of Antidementive Therapy: Drugs with a Specific Pharmacological Mechanism of Action

    Article • Current Pharmaceutical Design, January 2004, Bentham Science Publishers

    Hans-Juergen Moeller

  153. Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  154. Schizophrenie

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  155. Combination Therapy in Alzheimer???s Disease

    Article • CNS Drugs, January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  156. Herbst-/Winterdepression und Lichttherapie

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  157. Schizophrene Psychosen

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  158. Elektrokonvulsionstherapie

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  159. Schizoaffektive Psychosen und sonstige wahnhafte Störungen nicht organischer Genese

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  160. Novel Antipsychotics in the Long-term Treatment of Schizophrenia

    Article • The World Journal of Biological Psychiatry, January 2004, Taylor & Francis

    Hans-Juergen Moeller

  161. Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie

    Article • January 2004, Springer Science + Business Media

    Hans-Juergen Moeller

  162. Access to The World Journal of Biological Psychiatry

    Article • The World Journal of Biological Psychiatry, January 2004, Taylor & Francis

    Hans-Juergen Moeller

  163. SSRIs: Are the accusations justified

    Article • The World Journal of Biological Psychiatry, January 2004, Taylor & Francis

    Hans-Juergen Moeller

  164. Cincinnati criteria for mixed mania and suicidality in patients with acute mania

    Article • Comprehensive Psychiatry, January 2004, Elsevier

    Hans-Juergen Moeller

  165. Classification of Functional Psychoses and Its Implication for Prognosis: Comparison between ICD-10 and DSM-IV

    Article • Psychopathology, January 2004, Karger Publishers

    Hans-Juergen Moeller

  166. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity

    Article • Schizophrenia Research, November 2003, Elsevier

    Hans-Juergen Moeller

  167. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, October 2003, Elsevier

    Hans-Juergen Moeller

  168. Negative Symptoms in Depressed and Schizophrenic Patients

    Article • The Journal of Clinical Psychiatry, August 2003, Physicians Postgraduate Press, Inc

    Hans-Juergen Moeller

  169. Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression

    Article • Acta Neuropsychiatrica, August 2003, Cambridge University Press

    Hans-Juergen Moeller

  170. Genetic variations in tryptophan hydroxylase in suicidal behavior

    Article • Biological Psychiatry, August 2003, Elsevier

    Hans-Juergen Moeller

  171. Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression

    Article • Psychiatry Research, July 2003, Elsevier

    Hans-Juergen Moeller

  172. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial

    Article • Psychopharmacology, May 2003, Springer Science + Business Media

    Hans-Juergen Moeller

  173. Does considering duration of negative symptoms increase their specificity for schizophrenia?

    Article • Schizophrenia Research, April 2003, Elsevier

    Hans-Juergen Moeller

  174. The impact of the duration of untreated psychosis on short- and long-term outcome in schizophrenia

    Article • Current Opinion in Psychiatry, April 2003, Wolters Kluwer Health

    Hans-Juergen Moeller

  175. Kinematic Analysis of the Effects of Donepezil Hydrochloride on Hand Motor Function in Patients with Alzheimer Dementia

    Article • Journal of Clinical Psychopharmacology, April 2003, Wolters Kluwer Health

    Hans-Juergen Moeller

  176. Summer Birth and Deficit Schizophrenia

    Article • American Journal of Psychiatry, March 2003, American Psychiatric Association

    Hans-Juergen Moeller

  177. Dr. Sato and Colleagues Reply

    Article • American Journal of Psychiatry, February 2003, American Psychiatric Association

    Hans-Juergen Moeller

  178. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine

    Article • Psychopharmacology, January 2003, Springer Science + Business Media

    Hans-Juergen Moeller

  179. Psychiatrie und Psychotherapie

    Article • January 2003, Springer Science + Business Media

    Hans-Juergen Moeller

  180. Kommentar

    Article • January 2003, Springer Science + Business Media

    Hans-Juergen Moeller

  181. Effects of Haloperidol and Atypical Neuroleptics on Psychomotor Performance and Driving Ability in Schizophrenic Patients

    Article • Neuropsychobiology, January 2003, Karger Publishers

    Hans-Juergen Moeller

  182. On the Descriptive Validity of ICD-10 Schizophrenia: Empirical Analyses in the Spectrum of Non-Affective Functional Psychoses

    Article • Psychopathology, January 2003, Karger Publishers

    Hans-Juergen Moeller

  183. P300 subcomponents in obsessive-compulsive disorder

    Article • Journal of Psychiatric Research, November 2002, Elsevier

    Hans-Juergen Moeller

  184. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial

    Article • Psychopharmacology, November 2002, Springer Science + Business Media

    Hans-Juergen Moeller

  185. P300 subcomponents and clinical symptoms in schizophrenia

    Article • International Journal of Psychophysiology, March 2002, Elsevier

    Hans-Juergen Moeller

  186. Editorial

    Article • The World Journal of Biological Psychiatry, January 2002, Taylor & Francis

    Hans-Juergen Moeller

  187. Drug Treatment of Schizophrenia: State of the Art and the Potential of the Atypical Neuroleptics

    Article • January 2002, Springer Science + Business Media

    Hans-Juergen Moeller

  188. Plasma Catecholamines and Selective Slow Wave Sleep Deprivation

    Article • Neuropsychobiology, January 2002, Karger Publishers

    Hans-Juergen Moeller

  189. Anxiolytic Effects of Vigabatrin in Panic Disorder

    Article • Journal of Clinical Psychopharmacology, October 2001, Wolters Kluwer Health

    Hans-Juergen Moeller

  190. A polymorphism in the promoter of the serotonin transporter gene is not associated with suicidal behavior

    Article • Psychiatric Genetics, September 2001, Wolters Kluwer Health

    Hans-Juergen Moeller

  191. Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale

    Article • European Archives of Psychiatry and Clinical Neuroscience, June 2001, Springer Science + Business Media

    Hans-Juergen Moeller

  192. Corpus callosum and P300 in schizophrenia

    Article • Schizophrenia Research, April 2001, Elsevier

    Hans-Juergen Moeller

  193. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia

    Article • Schizophrenia Research, March 2001, Elsevier

    Hans-Juergen Moeller

  194. Pharmacological treatment of underlying psychiatric disorders in suicidal patients

    Article • February 2001, Taylor & Francis

    Hans-Juergen Moeller

  195. Depression und Demenz im Alter

    Article • January 2001, Springer Science + Business Media

    Hans-Juergen Moeller

  196. Einleitung

    Article • January 2001, Springer Science + Business Media

    Hans-Juergen Moeller

  197. Viewpoint: Past, Present and Future of Biological Psychiatry

    Article • The World Journal of Biological Psychiatry, January 2001, Taylor & Francis

    Hans-Juergen Moeller

  198. Empirical methodology as the main criterion of biological psychiatry

    Article • The World Journal of Biological Psychiatry, January 2001, Taylor & Francis

    Hans-Juergen Moeller

  199. Viewpoint: Methodological Issues in Psychiatry: Psychiatry as an Empirical Science

    Article • The World Journal of Biological Psychiatry, January 2001, Taylor & Francis

    Hans-Juergen Moeller

  200. Digitized analysis of abnormal hand–motor performance in schizophrenic patients

    Article • Schizophrenia Research, September 2000, Elsevier

    Hans-Juergen Moeller

  201. Clinical and Biological Findings in a Case With 48-Hour Bipolar Ultrarapid Cycling Before and During Valproate Treatment

    Article • The Journal of Clinical Psychiatry, August 2000, Physicians Postgraduate Press, Inc

    Hans-Juergen Moeller

  202. Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients

    Article • Schizophrenia Research, August 2000, Elsevier

    Hans-Juergen Moeller

  203. Age-transformation of hippocampal volumes improves diagnostic accuracy in Alzheimer's disease

    Article • Neurobiology of Aging, May 2000, Elsevier

    Hans-Juergen Moeller

  204. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial

    Article • European Neuropsychopharmacology, May 2000, Elsevier

    Hans-Juergen Moeller

  205. Die Rolle der Kognition in der Therapie Schizophrener Störungen

    Article • January 2000, Springer Science + Business Media

    Hans-Juergen Moeller

  206. Vorwort

    Article • January 2000, Springer Science + Business Media

    Hans-Juergen Moeller

  207. Resümee

    Article • January 2000, Springer Science + Business Media

    Hans-Juergen Moeller

  208. Atypical neuroleptics: a new approach in the treatment of negative symptoms

    Article • European Archives of Psychiatry and Clinical Neuroscience, December 1999, Springer Science + Business Media

    Hans-Juergen Moeller

  209. Effectiveness and Safety of Benzodiazepines

    Article • Journal of Clinical Psychopharmacology, December 1999, Wolters Kluwer Health

    Hans-Juergen Moeller

  210. Neuroscience and the future of psychiatry

    Article • Current Opinion in Psychiatry, November 1999, Wolters Kluwer Health

    Hans-Juergen Moeller

  211. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

    Article • Psychiatry Research, November 1999, Elsevier

    Hans-Juergen Moeller

  212. 21stSymposium of AGNP, Nuremberg, October 6thto 9th, 1999

    Article • Pharmacopsychiatry, July 1999, Thieme Publishing Group

    Hans-Juergen Moeller

  213. Reappraising neurotransmitter-based strategies

    Article • European Neuropsychopharmacology, April 1999, Elsevier

    Hans-Juergen Moeller

  214. Atypische Neuroleptika

    Article • January 1999, Springer Science + Business Media

    Hans-Juergen Moeller

  215. P300 subcomponents reflect different aspects of psychopathology in schizophrenia

    Article • Biological Psychiatry, January 1999, Elsevier

    Hans-Juergen Moeller

  216. Markers from event-related potential subcomponents and reaction time for information processing dysfunction in schizophrenia

    Article • European Archives of Psychiatry and Clinical Neuroscience, December 1998, Springer Science + Business Media

    Hans-Juergen Moeller

  217. The serotonin syndrome scale: first results on validity

    Article • European Archives of Psychiatry and Clinical Neuroscience, May 1998, Springer Science + Business Media

    Hans-Juergen Moeller

  218. Novel antipsychotics and negative symptoms

    Article • International Clinical Psychopharmacology, March 1998, Wolters Kluwer Health

    Hans-Juergen Moeller

  219. Serotonin Syndrome Scale

    Article • January 1998, American Psychological Association (APA)

    Hans-Juergen Moeller

  220. Schizophrenie — Moderne Konzepte zu Diagnostik, Pathogenese und Therapie

    Article • January 1998, Springer Science + Business Media

    Hans-Juergen Moeller

  221. The assessment of syndromes in schizophrenia: Current status and future perspectives

    Article • European Psychiatry, January 1998, Elsevier

    Hans-Juergen Moeller

  222. Treatment of negative symptoms in schizophrenia

    Article • European Psychiatry, January 1998, Elsevier

    Hans-Juergen Moeller

  223. Brofaromine versus imipramine in in-patients with major depression – a controlled trial

    Article • Journal of Affective Disorders, July 1997, Elsevier

    Hans-Juergen Moeller

  224. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

    Article • Neuroreport, May 1997, Wolters Kluwer Health

    Hans-Juergen Moeller

  225. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics

    Article • January 1997, Springer Science + Business Media

    Hans-Juergen Moeller

  226. Drug Treatment of Depression in the 1990s

    Article • Drugs, November 1996, Springer Science + Business Media

    Hans-Juergen Moeller

  227. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression — A study with single photon emission computed tomography

    Article • Psychiatry Research Neuroimaging, November 1996, Elsevier

    Hans-Juergen Moeller

  228. Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases

    Article • Schizophrenia Research, May 1996, Elsevier

    Hans-Juergen Moeller

  229. Therapeutischer Schlafentzug

    Article • January 1996, Springer Science + Business Media

    Hans-Juergen Moeller

  230. Therapie im Grenzgebiet von Psychiatrie und Neurologie

    Article • January 1996, Springer Science + Business Media

    Hans-Juergen Moeller

  231. Befunderhebung in der Psychiatrie: Lebensqualität, Negativsymptomatik und andere aktuelle Entwicklungen

    Article • January 1996, Springer Science + Business Media

    Hans-Juergen Moeller

  232. Involvement of mesial-temporal structures in rapid cycling mood disorders?

    Article • Human Psychopharmacology Clinical and Experimental, November 1995, Wiley

    Hans-Juergen Moeller

  233. Maintenance ECT for treatment of therapy-resistant paranoid schizophrenia and Parkinson's disease

    Article • Biological Psychiatry, June 1995, Elsevier

    Hans-Juergen Moeller

  234. Attempted suicide: Efficacy of treatment programs

    Article • Psychiatry and Clinical Neurosciences, May 1995, Wiley

    Hans-Juergen Moeller

  235. Newer and Older Monoamine Oxidase Inhibitors

    Article • CNS Drugs, February 1995, Springer Science + Business Media

    Hans-Juergen Moeller

  236. Brofaromine

    Article • CNS Drugs, January 1995, Springer Science + Business Media

    Hans-Juergen Moeller

  237. Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik

    Article • January 1994, Springer Science + Business Media

    Hans-Juergen Moeller

  238. Biochemical Findings of Negative Symptoms in Schizophrenia and Their Putative Relevance to Pharmacological Treatment

    Article • Neuropsychobiology, January 1994, Karger Publishers

    Hans-Juergen Moeller

  239. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

    Article • European Neuropsychopharmacology, March 1993, Elsevier

    Hans-Juergen Moeller

  240. Therapieresistenz unter Neuroleptikabehandlung

    Article • January 1993, Springer Science + Business Media

    Hans-Juergen Moeller

  241. Therapie im Grenzgebiet von Psychiatrie und Neurologie

    Article • January 1993, Springer Science + Business Media

    Hans-Juergen Moeller

  242. Psychische Krankheit im Alter

    Article • January 1993, Springer Science + Business Media

    Hans-Juergen Moeller

  243. Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs)

    Article • January 1993, Springer Science + Business Media

    Hans-Juergen Moeller

  244. Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia — an open study

    Article • European Neuropsychopharmacology, March 1992, Elsevier

    Hans-Juergen Moeller

  245. Aggression und Autoaggression

    Article • January 1992, Springer Science + Business Media

    Hans-Juergen Moeller

  246. Autoaggressives Verhalten — medikamentöse Behandlungsmöglichkeiten

    Article • January 1992, Springer Science + Business Media

    Hans-Juergen Moeller

  247. Hirnleistungsstörungen im Alter

    Article • January 1991, Springer Science + Business Media

    Hans-Juergen Moeller

  248. Antidepressiva: gestern und heute

    Article • January 1991, Springer Science + Business Media

    Hans-Juergen Moeller

  249. Care strategies for schizophrenic patients in a transcultural comparison

    Article • Comprehensive Psychiatry, September 1990, Elsevier

    Hans-Juergen Moeller

  250. Therapieresistenz unter Antidepressiva-Behandlung

    Article • January 1990, Springer Science + Business Media

    Hans-Juergen Moeller

  251. Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik

    Article • January 1990, Springer Science + Business Media

    Hans-Juergen Moeller

  252. Current Issues of Suicidology

    Article • January 1988, Springer Science + Business Media

    Hans-Juergen Moeller

  253. Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen

    Article • January 1987, Springer Science + Business Media

    Hans-Juergen Moeller

  254. Der Verlauf schizophrener Psychosen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  255. Untersuchungs- und Behandlungsverfahren in der Gerontopsychiatrie

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  256. Methodik und praktische Durchführung der Untersuchung

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  257. Einleitung und Problemstellung

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  258. Abschließende Zusammenfassung der wichtigsten Ergebnisse

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  259. Zweite Zwischenbilanz: Prä-Post-Vergleiche

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  260. Auswahl der Patientenstichprobe

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  261. Soziale, biographische und krankheitsbezogene Ausgangsdaten

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  262. Prädiktoren/Einflußgrößen: Ergebnisse multivariater Analysen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  263. Zustand bei Katamnese

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  264. Self-Constructed Outcome Ratings

    Article • January 1986, American Psychological Association (APA)

    Hans-Juergen Moeller

  265. Probleme und Ergebnisse der Katamneseforschung über schizophrene Erkrankungen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  266. Beziehungen zwischen den Katamnesedaten als Beispiel für die Zusammenhänge von multimethodal erhobenen Daten

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  267. Siebte Zwischenbilanz: Vorhersagekraft von Prognose-Skalen sowie prädiktive Validität operationalisierter Schizophrenie-Diagnostik

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  268. Behandlung im MPIP und Krankheitsverlauf im Katamnesezeitraum

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  269. Fünfte Zwischenbilanz: Optimale Kombination von Prädiktoren und die prognostische Relevanz von psychopathologischen Merkmalen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  270. Neuroleptika-Therapie und ihre Bedeutung als Einflußgröße im Katamnesezeitraum

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  271. Informationen über verstorbene, die Untersuchung verweigernde oder nicht auffindbare Patienten

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  272. Computerisierte Überprüfung der klinisch intuitiv gestellten Diagnosen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  273. Prädiktionsmöglichkeiten durch alleinige Kombination der prognostisch relevantesten psychopathologischen Befunddaten

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  274. Vergleich des psychopathologischen Befundes zwischen Aufnahme, Entlassung und Katamnese

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  275. Verbesserung der prognostischen Möglichkeiten durch Einbeziehung von Selbstbeurteilungsdaten über den psychopathologischen Befund

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  276. Auftretenshäufigkeit und Verlaufsmuster depressiver Zustände im Verlauf der stationären Akutbehandlung schizophrener Patienten mit Neuroleptika

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  277. Prädiktoren/Einflußgrößen: Ergebnisse der Produkt-Moment-Korrelationsanalysen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  278. Erste Zwischenbilanz: Soziodemographische und anamnestische Ausgangsdaten, Behandlung im Index-Zeitraum und Zustand bei Katamnese

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  279. Belastung durch Lebensereignisse und ihre Bedeutung als Einflußgröße im Katamnesezeitraum

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  280. Vierte Zwischenbilanz: Mehrdimensionale „outcome“-Diagnostik und univariate Prädiktoranalysen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  281. Unzureichender Therapieerfolg unter neuroleptischer Akutbehandlung und seine Vorhersagbarkeit

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  282. Prä-Post-Vergleich sozialer und krankheitsbezogener Daten

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  283. Prädiktoren/Einflußgrößen: Ergebnisse der Subgruppenvergleiche und biseriale Korrelationsanalysen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  284. Sechste Zwischenbilanz: Lebensereignisse und Neuroleptika-Therapie als fraglich verlaufsmodifizierende Faktoren im Katamnesezeitraum

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  285. Die prämorbide Persönlichkeit Schizophrener und das Problem ihrer standardisierten Erfassung

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  286. Vorhersage des Langzeitverlaufs schizophrener Psychosen auf der Basis von Prognose-Skalen: Wert und Vergleich verschiedener Prognose-Skalen

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  287. Dritte Zwischenbilanz: Unzureichender Behandlungserfolg und Auftreten depressiver Symptomatik im Verlauf der stationären Behandlung mit Neuroleptika

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  288. Operationalisierte Schizophrenie-Diagnostik (DSM-III, RDC), ihre Beziehung zur traditionellen und ICD-Diagnostik und ihre prädiktive Validität

    Article • January 1986, Springer Science + Business Media

    Hans-Juergen Moeller

  289. Can Suicide Prevention be Effective?

    Article • January 1985, Springer Science + Business Media

    Hans-Juergen Moeller

  290. The Nature of the Depressive Syndrome in Schizophrenia and its Relationship to Prognosis

    Article • January 1985, Springer Science + Business Media

    Hans-Juergen Moeller

  291. Probleme der psychiatrischen Wissenschaftssprache

    Article • Methods of Information in Medicine, October 1976, Thieme Publishing Group

    Hans-Juergen Moeller

  292. Angststörungen

    Article • Springer Science + Business Media

    Hans-Juergen Moeller

  293. Schizophrene und schizophreniforme Störungen

    Article • Springer Science + Business Media

    Hans-Juergen Moeller

  294. Antidepressant treatment of bipolar depression

    Article • Springer Science + Business Media

    Hans-Juergen Moeller

  295. Schizophrene und schizophreniforme Störungen

    Article • Springer Science + Business Media

    Hans-Juergen Moeller

  296. Methodological Issues in Psychiatry: Psychiatry as an Empirical Science

    Article • De Gruyter

    Hans-Juergen Moeller